TNXP - Tonix Pharmaceuticals Holding Corp.
| Previous Close | 0.4701 |
| Open | 0.4701 |
| Bid | 0.4500 x 1000 |
| Ask | 0.4860 x 900 |
| Day's Range | 0.4600 - 0.4860 |
| 52 Week Range | 0.3700 - 9.9000 |
| Volume | 117,827 |
| Avg. Volume | 587,195 |
| Market Cap | 7.242M |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.2510 |
| Earnings Date | Nov 7, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.93 |
- GlobeNewswire
Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the 2019 annual National Association of Veterans’ Research and Education Foundations’ (NAVREF) Conference being held September 15-18, 2019, in San Antonio, Texas. Tonix is a Silver Sponsor of this event. Formed in 1992, NAVREF is the 501(c)(3) nonprofit membership organization of research and education foundations affiliated with Department of Veterans Affairs (VA) medical centers.
- GlobeNewswire
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
NEW YORK, Sept. 10, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at three upcoming.
- GlobeNewswire
Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that participants were dosed in a Phase 1 study evaluating the safety, tolerability and pharmacokinetics (PK) of TNX-601 (tianeptine oxalate) for the daytime treatment of posttraumatic stress disorder (PTSD). Topline data from this study investigating new modified release formulations are expected later this year. “We are excited to leverage our expertise in PTSD and further our development of TNX-601 as a potential daytime treatment for PTSD,” said Seth Lederman, M.D., Tonix’s President and Chief Executive Officer.
- Simply Wall St.
Should You Take Comfort From Insider Transactions At Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- GlobeNewswire
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection
Tonix and MGH have agreed to work jointly under a research agreement which will bring together Tonix’s internally developed, proprietary anti-CD154 mAb, TNX-1500, with transplantation experts from MGH, led by Richard N. Pierson III, M.D., scientific director of the Center for Transplantation Sciences in the Department of Surgery at MGH and Professor of Surgery at Harvard Medical School (HMS).
- GlobeNewswire
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
NEW YORK, Aug. 20, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today an exclusive.
- GlobeNewswire
Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
Enrollment Continues for Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD; Topline Data Expected First Half of 2020 Pipeline Expanded in Addiction Medicine with.
- GlobeNewswire
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced that Patrick Grace stepped down from the Company’s Board of Directors, effective August 1, 2019. Mr. Grace has been a member of Tonix’s Board of Directors since 2011. “It has been my privilege to have worked with the Board and the management team of Tonix," said Patrick Grace.
- GlobeNewswire
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,357,465 to the Company on July 23, 2019. This patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride,” includes 14 claims directed to eutectics of cyclobenzaprine hydrochloride and mannitol and methods of making those eutectics. This patent is expected to provide Tonix with U.S. market exclusivity until 2035. Tonix’s proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for chronic sublingual (under-the-tongue) administration daily at bedtime, which facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism.
- GlobeNewswire
Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the closing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $0.60 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 1,350,000 additional shares to cover overallotments, if any. The Company expects to use the net proceeds from this offering to help fund Phase 3 development for its lead product candidate, TNX-102 SL, to advance the development of a recently in-licensed product candidate, TNX-1300, and for working capital and other general corporate purposes.
- GlobeNewswire
Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $0.60 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to help fund Phase 3 development for its lead product candidate, TNX-102 SL, to advance the development of a recently in-licensed product candidate, TNX-1300, and for working capital and other general corporate purposes.
- GlobeNewswire
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric, pain and addiction conditions as well as to improve biodefense, today announced that the China National Intellectual Property Administration issued Chinese Patent No. ZL 201480024011.1 to the Company on April 16, 2019. Tonix’s proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for long-term daily use at bedtime and sublingual (under-the-tongue) administration, which facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism.
- Zacks Small Cap Research
TNXP: Enrollment Continues for Phase 3 Trial of TNX-102 SL in PTSD…
In March 2019, Tonix Pharmaceuticals Holding Corp. (TNXP) announced the first patient has been enrolled in the RECOVERY Phase 3 study of TNX-102 SL in patients with posttraumatic stress disorder (PTSD). The RECOVERY trial is a randomized, double blind, placebo controlled study of TNX-102 SL over 12 weeks with the primary endpoint being the Week 4 change in CAPS-5 score from baseline between TNX-102 SL and placebo-treated patients. 1) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later.
- GlobeNewswire
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
NEW YORK, May 30, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing small.
- GlobeNewswire
Tonix Pharmaceuticals to Present at BIO 2019 International Convention
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix will present at the BIO 2019 International Convention held June 3-6, 2019, in Philadelphia, PA. A live webcast and subsequent archived recording of the Company presentation will be available under the IR Events tab of the Investor Relations section of the Tonix Pharmaceuticals website at www.tonixpharma.com.
- Simply Wall St.
How Does Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Affect Your Portfolio Volatility?
If you own shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) then it's worth thinking about how it...
- GlobeNewswire
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
Phase 2 Program Granted Breakthrough Therapy Designation by FDA Emergency Room Visits for Cocaine Abuse Total More than 500,000 Annually in U.S. NEW YORK, May 23, 2019.
- GlobeNewswire
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
NEW YORK, May 21, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of.
- GlobeNewswire
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense, today announced financial results for the quarter ended March 31, 2019 and an overview of recent operational highlights. Tonix’s lead program is TNX-102 SL, or Tonmya* (cyclobenzaprine HCl sublingual tablets), for the treatment of posttraumatic stress disorder (PTSD), which was granted Breakthrough Therapy designation and which is currently being studied in a Phase 3 efficacy trial. The FDA also advised that the long-term safety exposure data from the Company’s PTSD program may be used to support a New Drug Application (NDA) for the treatment of fibromyalgia. It is estimated that between 5-10 million adults in the U.S. are affected by fibromyalgia, of which approximately 3 million are diagnosed.
- GlobeNewswire
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleased to welcome Dr. Goodman to the Tonix Board, as he brings 20 years of biopharmaceutical research and development leadership experience that will be invaluable to Tonix as we grow the company.
- GlobeNewswire
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), announced on April 18, 2019 that the Company received a notice of termination, effective April 29, 2019, whereby USAMMDA is exercising its contractual right to terminate without cause the CRADA entered into on December 4, 2015 between the Company and USAMMDA relating to the development of Tonmya* or TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of Posttraumatic Stress Disorder (PTSD). The termination does not affect Tonix’s finances or the conduct of the ongoing RECOVERY trial in PTSD.
- GlobeNewswire
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
NEW YORK, April 22, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical.
- Zacks Small Cap Research
TNXP: Phase 3 Trial of TNX-102 SL in PTSD Underway…
On March 11, 2019, Tonix Pharmaceuticals Holding Corp. (TNXP) announced the first patient has been enrolled in the RECOVERY Phase 3 study of TNX-102 SL in patients with posttraumatic stress disorder (PTSD). The RECOVERY trial is a randomized, double blind, placebo controlled study of TNX-102 SL over 12 weeks with the primary endpoint being the Week 4 change in CAPS-5 score from baseline between TNX-102 SL and placebo-treated patients. 1) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later.
